Calliditas Therapeutics AB Accounts Payable

Calliditas Therapeutics AB (CALT) currently reports a accounts payable of $150M as of June 2024. That compares with $72M in the prior-year period — up 109.6% year over year. Use the charts on this page to explore Calliditas Therapeutics AB's accounts payable history and peer comparisons.

Calliditas Therapeutics AB's accounts payable increased from $72M to $150M — a 109.6% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Calliditas Therapeutics AB reported $150M in accounts payable as of June 2024. That compares with $72M in the prior-year period — up 109.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Calliditas Therapeutics AB, and consider following CALT for alerts when major investors trade the stock.

Calliditas Therapeutics AB is classified in the Healthcare sector. On accounts payable, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CALT with unrelated industries.